Microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers from clinical datasets. Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products. Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair. It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche in IBD, and University of Adelaide in Ulcerative Colitis.